Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

814P - Clinical significance of isolated pulmonary recurrence in patients with endometrioid endometrial cancer who achieved complete remission after primary treatment

Date

21 Oct 2023

Session

Poster session 11

Topics

Tumour Site

Endometrial Cancer

Presenters

Jigeun Yoo

Citation

Annals of Oncology (2023) 34 (suppl_2): S507-S542. 10.1016/S0923-7534(23)01937-3

Authors

J. Yoo1, S. Lee2, S.I. Kim3, I.S. Hwang4, J. Choi5, K.H. Lee6

Author affiliations

  • 1 Obstetrics And Gynecology, The Catholic University of Korea - Daejeon St. Mary's Hospital, 34943 - Daejeon/KR
  • 2 Obstetrics And Gynecology Department, The Catholic University of Korea - Seoul St. Mary's Hospital - Catholic Medical Center, 137-701 - Seoul/KR
  • 3 Obstetrics And Gynecology, The Catholic University of Korea - St. Vincent's Hospital, 442-723 - Suwon/KR
  • 4 Obstetrics And Gynecology, The Catholic University of Korea - Seoul St.Mary Hospital, 06591 - Seoul/KR
  • 5 Obstetrics And Gynecology, The Catholic University of Korea - College of Medicine, 06591 - Seoul/KR
  • 6 222 Banpodaero Seochogu, The Catholic University of Korea - College of Medicine, 06591 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 814P

Background

This study was to evaluate the clinical significance of pulmonary recurrence for patients who achieved complete remission after primary treatment of endometrioid endometrial cancer.

Methods

This multicenter retrospective study included patients who had undergone primary treatment for endometrial cancer at six different hospitals between 2009 and 2019. Inclusion criteria were patients with endometrioid histology and no evidence of residual disease after primary treatment including standard surgical procedure. Patients who developed pulmonary metastasis during follow-up were identified. Time to second objective disease progression (PFS2) was defined as time from the start of second-line therapy to second recurrence, and second-line overall survival (OS2) was defined as time from the start of second-line therapy to death.

Results

Of the 1074 patients who met the inclusion criteria, 90 experienced recurrences. Pulmonary recurrence was the most frequent site of first recurrence, accounting for 34.4% (31/90) of all recurrences. Isolated pulmonary recurrence accounted for 64.5% (20/31) of all pulmonary recurrences, whereas 35.5% (11/31) of patients had concurrent recurrences at other sites. The median PFS2 and OS2 of patients with isolated pulmonary recurrence were significantly longer than those with concurrent recurrences at other sites (PFS2, 17.0 vs. 9.0 months, log-rank P = 0.004; OS2, not reached vs. 28.0 months, log-rank P = 0.001). During the median follow-up period of 88.0 months, 73.7% of patients with isolated pulmonary recurrence had recurrence or progression after second-line treatment, but only 15.8% of the patients died. On the other hand, during the median follow-up period of 33.0 months, 88.9% of patients with concurrent recurrence at other sites had recurrence or progression after second-line treatment and 66.7% died. Multivariable analysis identified isolated pulmonary recurrence as an independent factor for longer OS2 (HR, 0.18; 95% CI, 0.03-0.59; P = 0.009).

Conclusions

Our study showed that isolated pulmonary recurrence is associated with prolonged OS2 in patients with recurrent endometrioid endometrial cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.